SureTrader Advertisement
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: Dip66
Search This Board:
Last Post: 6/29/2016 9:21:24 AM - Followers: 538 - Board type: Free - Posts Today: 0

MultiCell Technologies, Inc. (MCET)

(U.S. Reporting: SEC Filer) 

Outstanding shares 5,000,948,700 as of Jul 8, 2015 

Office: (401) 762-0045  |  Email:

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)




MultiCell inks R&D agreement with Oxis Biotech

MultiCell Technologies (OTCPK: MCET) subsidiary MultiCell Immunotherapeutics enters into a research and development and product license agreement with Oxis Biotech (OTCQB: OXIS) to create three novel antibody-drug conjugates (ADCs) based on Oxis' lead drug candidates and MultiCell's proprietary ADC platform technology. The ADCs will be targeted for the treatment of triple-negative breast cancer and multiple myeloma and associated osteolytic lesions.

Under the terms of the agreement, Oxis will pay MultiCell a license fee of $500K, up to $12.75M in clinical development milestones and a royalty of 3% on net sales. Oxis will also reimburse MultiCell up to $1.125M in development costs. MultiCell grants Oxis an option to purchase manufacturing rights to the three ADCs upon the payment of an additional $10M.

MultiCell retains all rights to its ADC platform for all indications and is free to pursue its own drug development programs and to partner with other firms.

Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:

MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

 Therapeutic Candidate  


    Discovery Optimization    

    Preclinical Development    

    Phase 1    

    Phase 2/b   

    Phase 3    



yes yes yes yes  



yes yes      



yes yes      



yes yes      

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc. Corporate Headquarters

68 Cumberland Street, Suite 301
Woonsocket, RI 02895

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

Find us on Google Maps  

 Management and Board of Directors

Barbara (Corbett) Newmin - Investor Relations

W. Gerald Newmin, Chairman and Chief Executive Officer

Dr. Steve Chang Ph. D., Director

Grant Miller, Director


Alan Tuchman, M.D.

Thomas A. Page, Director

Edward Sigmond, Director


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MCET News: Statement of Ownership (sc 13g) 02/16/2016 06:20:13 AM
#41357   This stock is DOA and we all know it ctvette2003 06/29/16 09:21:24 AM
#41356   Report delivers insight into the hepatocellular carcinoma pipeline TPX 06/28/16 12:22:33 PM
#41355   Simon Wagstaff is a character in a book simon wagstaff 06/12/16 12:21:15 PM
#41354   I hear you. I'm just going to point Dip66 06/12/16 10:47:56 AM
#41353   Perhaps you think too much. simon wagstaff 06/12/16 08:22:28 AM
#41352   Simon, you were a former exe at MultiCell no? Dip66 06/11/16 11:38:15 AM
#41351   Just a hobby, not like it takes any simon wagstaff 06/11/16 08:28:33 AM
#41350   Simon, I know your a cornerstone here, but bontooth 06/11/16 03:03:58 AM
#41349   This is a little misleading, thank you. Only simon wagstaff 06/08/16 01:35:26 PM
#41348   Patents by Assignee Multicell Immunotherapeutics, Inc. TPX 06/08/16 10:36:11 AM
#41347   Just the same old games ctvette2003 06/07/16 07:04:12 PM
#41346   That one I can figure out. 200,000 shares, simon wagstaff 06/07/16 02:18:54 PM
#41345   .0003's printing getting interesting. Dip66 06/07/16 11:39:26 AM
#41344   12 million times .0002. I don't know, 24 simon wagstaff 06/07/16 10:45:39 AM
#41343   I'm not disagreeing but your math is off presidentsclub 06/07/16 10:32:17 AM
#41342   You're wasting time here this turd was flushed ctvette2003 06/06/16 02:39:48 PM
#41341   MultiCell Immunotherapeutics (MCIT) Next Generation Antibody Therapies Market TPX 06/06/16 02:10:33 PM
#41340   Pay attention. Money already came and went. simon wagstaff 06/03/16 02:41:50 PM
#41339   in the latest 10 q for OXIS The dead cat bouncer 06/03/16 02:13:02 PM
#41338   The MM pass it around to make it simon wagstaff 06/03/16 07:14:52 AM
#41337   Trying to move here Penny_God 06/02/16 01:46:29 PM
#41336   With OXIS receiving recent funding I have a Dip66 06/02/16 11:28:17 AM
#41335   12 million buy something is going on redsox17 06/02/16 10:52:02 AM
#41334   300 bucks will get you a nice dinner simon wagstaff 06/01/16 08:54:07 AM
#41333   3m VOLUME, Barbara must have needed money for ctvette2003 05/31/16 10:47:33 AM
#41332   I don't really think they have done anything simon wagstaff 05/23/16 02:09:55 PM
#41331   I find it amazing how Barbara Newmin (HEAD Dip66 05/23/16 11:55:48 AM
#41330   2nd that ctvette2003 05/20/16 11:15:21 AM
#41329   I think you should spend the $2000.00 for simon wagstaff 05/20/16 09:28:05 AM
#41328   2016 Pipeline of Hepatitis C Market Covering 84 Companies TPX 05/20/16 07:15:02 AM
#41327   Goodness, now there is a reliable source! simon wagstaff 05/19/16 11:18:02 AM
#41326   PR Newswire redsox17 05/19/16 08:57:10 AM
#41325   La Jolla must not be happy owning 10%+/- Dip66 05/17/16 04:00:01 PM
#41324   I started here. Good education not to trust Latinachica 05/16/16 09:35:48 PM
#41323   I will just point out once again that simon wagstaff 05/10/16 06:44:21 AM
#41322   Looks like they just take are money and ferenc 05/09/16 09:36:19 AM
#41321   Barbara, Gerald or Steve come on give me The Future 05/04/16 05:36:27 PM
#41320   News is in the pipeline The dead cat bouncer 05/04/16 01:02:52 PM
#41319   They don't report anymore? How come ? ferenc 05/04/16 08:33:09 AM
#41318   HaHaHaHa! Wrong board I think. simon wagstaff 05/03/16 07:23:49 AM
#41317   Yeah, after a 1:10000 RS. Happened to me andre b 05/02/16 05:53:01 PM
#41316   This could easily go to $1.00 just watch WtdoIknow 05/02/16 03:32:47 PM
#41315   What hope? They have deleted just about everything simon wagstaff 04/29/16 09:13:36 AM
#41314   MCET, can you at least throw us a The Future 04/28/16 05:42:49 PM
#41313   Interesting activity on Level II. 6.3M in volume. Dip66 04/22/16 12:15:42 PM
#41312   What happened? Feels like a ghost town. Long The Future 04/21/16 11:37:17 PM
#41311   Entire portfolio is green today, MCET red, as Dip66 04/18/16 02:55:07 PM
#41310   Posting on MultiCell's FB page is like using SnapChat. mrroundtree 04/15/16 04:46:46 PM
#41309   Flip the switch and get this going! Dip66 04/15/16 10:47:49 AM
#41308   ..come on mcet, you can do it, mark5050 04/15/16 09:51:22 AM